Diamyd Medical AB (publ) (FRA:DMN)
Germany · Delayed Price · Currency is EUR | Market Cap | 14.08M -89.6% |
| Revenue (ttm) | 42.87K +266.9% |
| Net Income | -22.97M |
| EPS | -0.16 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500 |
| Open | 0.0708 |
| Previous Close | 0.0717 |
| Day's Range | 0.0708 - 0.0708 |
| 52-Week Range | 0.0539 - 1.8000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 7, 2026 |
About Diamyd Medical AB
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. It develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 201... [Read more]
Financial Performance
In fiscal year 2026, Diamyd Medical AB's revenue was 477,000, an increase of 266.92% compared to the previous year's 130,000. Losses were -255.59 million, 50.5% more than in 2025.
Financial numbers in SEK Financial StatementsNews
Diamyd Medical AB Quarterly report: Q4 2026
Diamyd Medical AB has published its Q4 2026 quarterly earnings report on October 7, 2026.
Diamyd Medical AB Quarterly report: Q3 2026
Diamyd Medical AB has published its Q3 2026 quarterly earnings report on June 24, 2026.
Diamyd Medical AB Transcript: Study result
Interim phase III results for retogatein in type 1 diabetes showed futility, with no efficacy observed in any subgroup, contradicting prior positive data. A thorough investigation is underway, and the trial continues until the root cause is determined. Cash position remains strong at $40 million.
Diamyd Medical AB Press release: Study result
Diamyd Medical AB issued a press release on March 30, 2026, disclosing material business information to investors.
Diamyd Medical AB Slides: Company presentation
Diamyd Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Diamyd Medical AB Transcript: Q2 25/26
Full enrollment in a pivotal phase III trial, $25M in new U.S. financing, and a successful GMP inspection mark major milestones. Additional conditional funding could bring total new cash to $160M, supporting trial completion and pre-commercial activities.
Diamyd Medical AB Quarterly report: Q2 2026
Diamyd Medical AB has published its Q2 2026 quarterly earnings report on March 25, 2026.
Diamyd Medical AB Transcript: Lilla Lördag
A precision medicine approach targeting HLA-defined subgroups in type 1 diabetes is under phase III evaluation, with interim results expected soon. Early data suggest efficacy depends on genetic selection, and regulatory pathways may allow accelerated approval if results are positive.
Diamyd Medical AB Slides: Company presentation
Diamyd Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on February 7, 2026.
Diamyd Medical AB Quarterly report: Q1 2026
Diamyd Medical AB has published its Q1 2026 quarterly earnings report on January 28, 2026.
Diamyd Medical AB Transcript: Status update
Primary efficacy readout for the phase 3 trial has been moved up to 15 months, with interim results expected in March 2026. Early positive data could enable accelerated FDA approval, and durability will still be assessed at 24 months.
Diamyd Medical AB Transcript: Status Update
Type 1 diabetes research is advancing rapidly, with precision medicine and immune tolerance therapies leading the way. Diamyd Medical's GAD65-based phase III trial targets genetically defined patients, with an interim readout in March that could accelerate FDA approval. Optimism is high for significant breakthroughs and expanded patient access in the coming years.